CN Patent

CN116889552B — 一种安全、稳定的注射用尼莫地平及其制备方法

Assigned to Baolong Pharmaceutical Co ltd · Expires 2025-12-19 · 0y expired

What this patent protects

本发明涉及医药技术领域，具体是一种安全、稳定的注射用尼莫地平及其制备方法。本发明提供了一种含磺丁基醚‑β‑环糊精的尼莫地平环糊精冻干粉针，可显著提高尼莫地平溶解性、用药安全性和稀释稳定性，增加患者使用的顺应性及临床使用的便捷性。本发明与市售尼膜同注射液相比，安全性和稀释稳定性均有显著提升，具有明显优势。

USPTO Abstract

本发明涉及医药技术领域，具体是一种安全、稳定的注射用尼莫地平及其制备方法。本发明提供了一种含磺丁基醚‑β‑环糊精的尼莫地平环糊精冻干粉针，可显著提高尼莫地平溶解性、用药安全性和稀释稳定性，增加患者使用的顺应性及临床使用的便捷性。本发明与市售尼膜同注射液相比，安全性和稀释稳定性均有显著提升，具有明显优势。

Drugs covered by this patent

nicardipine-hydrochloride (NICARDIPINE HYDROCHLORIDE)

Patent Metadata

Patent number: CN116889552B
Jurisdiction: CN
Classification: —
Expires: 2025-12-19
Drug substance claim: No
Drug product claim: No
Assignee: Baolong Pharmaceutical Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.